Antiviral activity of Tecovirimat against Mpox virus clades 1a, 1b, 2a and 2b
Postal, J.; Guivel-Benhassine, F.; Porrot, F.; Grassin, Q.; Crook, J.; Vernuccio, R.; Caro, V.; Vanhomwegen, J.; Guardado-Calvo, P.; Simon-Loriere, E.; Dacheux, L.; Manuguerra, J.-C.; Schwartz, O.
Show abstract
The recent Mpox virus (MPXV) outbreak was caused by a novel and more pathogenic clade 1b virus. We compared the antiviral efficacy of Tecovirimat in cell culture, against the two ancestral clades 1a and 2a, the clade 2b that circulated in 2022, and the recent clade 1b virus. We report that Tecovirimat similarly inhibits the replication of all four MPXV clades, at nanomolar concentrations (nM). Our results suggest that Tecovirimat remains a therapeutic option against the latest clade 1b virus.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.